



Sheet 1 of 1

Information Disclosure Statement Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 31113/C720	Serial No. 10/582,279
INFORMATION DISCLOSURE STATEMENT		Applicant Klock et al.			
		Filing Date June 9, 2006		Group	

U.S. PATENT DOCUMENTS							
*Examiner Initials	Document Number	Publication Date	Name	Class	Subclass	Filing Date if Appropriate	
/SL/	US 2005/022020	10/6/2005	Freyberg, et al.	514	12		

FOREIGN PATENT DOCUMENTS						
*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation
						Yes No
/SL/	DE 101 63 130	10/6/2005	Germany			X
/SL/	WO 03/054009	07/03/03	PCT			
/SL/	WO 02/26932	04/04/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
/SL/	Agrawal, "Antisense Oligonucleotides Towards Clinical Trials," <i>Tibtech</i> , vol. 14, pp. 376-387, October, 1996
	Cerchia et al., "Nucleic Acid Aptamers in Cancer Medicine," <i>FEBS Letters</i> , vol. 528, pp. 12-16, August 28, 2002
	Ellington et al., "Aptamers as Potential Nucleic Acid Pharmaceuticals," <i>Biotechnology Annual Review</i> , vol. 1, pp. 185-214, 1995
	Famulok, "Oligonucleotide Aptamers that Recognize Small Molecules," pp. 324-329
	Freyberg et al., "Proatherogenic Flow Conditions Initiate Endothelial Apoptosis via Thrombospondin-1 and the Integrin-Associated Protein," <i>Biochemical and Biophysical Research Communications</i> , vol. 286, pp. 141-149, 2001
	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> , vol. 64, pp. 763-797, 1995
	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <i>Clinical Chemistry</i> , vol. 45, no. 9, pp. 1628-1650, 1999
	Köhler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> , vol. 256, pp. 495-497, 1975
	Osborne et al., "Nucleic Acid Selection and the Challenge of Combinatorial Chemistry," <i>Chem. Rev.</i> , vol. 97, pp. 349-370, 1997
	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> , vol. 253, pp. 314-317, July 19, 1991
	Ruckman et al., "2'-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF 165)," <i>The Journal of Biological Chemistry</i> , vol. 273, no. 32, pp. 20556-20567, August 7, 1998
W	The Eyetech Study Group, "Preclinical and Phase 1A Clinical Evaluation of an Anti-

/Scott Long/

08/21/2007

	/SL/	VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration," <i>The Journal of Retinal and Vitreous Diseases</i> , vol. 22, no. 2, pp. 143-151, 2002
--	------	---

Examiner	/Scott Long/	Date Considered	08/21/2007
<p><b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			